2021-08-002 + 2019-06-002 + 2019-05-005 - MetalA-MDR 05 - New metal-antibiotics against multidrug-resistant bacteria

Develop an innovative metalloantibiotic based on gold (III) to treat all types of infections caused by MDR bacteria

2023-12-015 + 2021-08-009 - ALL-BePrecise-2 - Precision medicine in infant t(4;11) pro-B-ALL: targeting the novel biomarker HDAC7

Acute lymphoblastic leukemia (ALL) derived from B cell progenitors (pro-B-ALL) is the most prevalent type of cancer among children that are annually diagnosed of leukemia in Western countries. Despite an 80% of pediatric B-ALL remission has been achieved, a specific subgroup of infant patients (<1 year old) that present a translocation between chromosomes 4 and 11, commonly relapse, converting acute leukemia into the main cause of pediatric cancer-associated death. Survival rate of infants diagnosed with t(4;11) pro-B-ALL does not even reach 35%. Due to their short age and vulnerability, these patients are normally excluded from clinical trials rendering them to no further opportunities than non-targeted chemotherapy or "off-label" use of available drugs. Therefore, there is an urgent need to improve current available therapies. Recently, Dr Maribel Parra's group has identified HDAC7 as a prognostic factor in infants with this aggressive leukemia. These patients display a general loss in HDAC7 expression. The lowest levels of HDAC7 are associated with a poor outcome of the patients. Additional results show that HDAC7 is also lost in adult patients with t(4;11) pro-B-ALL and diffuse large B cell lymphoma (DLBCL), both aggressive diseases with low survival. Therefore, the identification of those blood cancer patients with low HDAC7 levels is a promising approach to implement personalized medicine strategies aiming to specifically induce HDAC7 expression. In this sense, a novel combinatorial therapy is being developed comprising MI-538 and Chidamide with the capacity to trigger HDAC7 expression in t(4;11) pro-B-ALL cells.

2021-08-005 - uSDN-03 - A cloud-native network controller for 5G networks and beyond

A cloud native SDN controller enabling smart networks and services for 6G and beyond. Based on a cloud-native, micro-services architecture, TeraFlow can be integrated with other network elements, providing end to end network orchestration and control and a versatile toolbox for flow aggregation, management, network equipment integration, AI and ML-based security, and forensic evidence for multi-tenancy.

2024-13-020 + 2021-08-011 + 2020-07-012 - Compound H/pro-H 03 - Novel pre-clinical candidates for immune-oncology (compound H and pro-H)

We have generated two small molecule TGF-beta receptor type 1 (TGFBRI (ALK5)) inhibitors: compound H and its prodrug (pro-H), with clear innovation potential over competitors under development, since they are efficacious at a tolerable dose.

2021-08-004 - ARVIS - ARTIFICIAL VISION SYSTEM

An artificial vision system including a visual prosthesis comprising an integrated circuit comprising a plurality of pixels, an array of electrodes connected to the pixels and configured to excite neurons in a retina, and one or more PV cells. The implant furthermore comprises a photodetector. The integrated circuit is configured to process signals from the photodetector to selectively activate the pixels.

2021-08-003 - ELECTRA - Energy-efficient electrodes for the production of green hydrogen based on metal oxides

Next generation electrodes for enhanced electrolysers and fuel cells. Innovative catalytic coatings for industrial electrodes.

2021-08-012 + 2019-06-008 - ONCOBOTS - The use of self-propelled urease nanoparticles for the treatment of non-invasive bladder cancer

ONCOBOTS is a patented technology based on enzyme-powered nanomotors, which are capable to navigate in fluids due to the biocatalytic decomposition of fuel contained in body fluids. ONCOBOTS core can be loaded with anticancer drugs and their surface can also include additional moieties, such as antibodies for cancer targeting, PEG for immune system camouflaging, or markers for fluorescence detection.

2021-08-008 - DOWI - Motor de optimización DASH para redes inalámbricas

2021-08-001 - NeurAntigenv2 - A Human Neural Platform for Assaying Antigen- Antibody Interactions for Autoimmune Encephalitis

A Human Neural Platform for Assaying Antigen- Antibody Interactions for Autoimmune Encephalitis